Mifepristone (RU-486) in Androgen Independent Prostate Cancer

Inclusion Criteria

• •Histologic documentation of adenocarcinoma of the prostate
• •Bone metastasis(es) by bone scan or cat scan
• •Clinical, biochemical, or radiographic progression after primary androgen ablation with either orchiectomy or gonadotropin releasing hormone analog therapy.
• •One prior chemotherapy treatment is allowed.
• •\> 3 weeks since major surgery
• •\> 4 weeks since radiotherapy
• •\> 8 weeks since prior strontium-89 or samarium 153
• •ECOG performance status 0 or 1
• •Absolute neutrophil count (ANC) \> 1,500/ul
• •Platelets \> 100,000/ul
• •Bilirubin \< 1.5 x upper limit of normal (ULN)
• •AST or ALT \< 3 x ULN
• •Creatinine \< 1.5 x ULN
• •Electrolytes within 10% of normal range
• •Serum testosterone \< 50ng/dL
• •Prostate-specific antigen (PSA) \> 5.0ng/ml